“baxalta” Archives

in
Entry Author Date Location
Roche Gets FDA OK for Injectable Version of Breast Cancer Drug 06/29/20 San Diego
Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M 02/06/19 San Diego
Halozyme Inks $105M Bristol-Myers Partnership, Expands Roche Deal 09/14/17 San Diego
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? 02/16/17 New York
Bio Roundup: Mylan Grilled, Duchenne Kids Thrilled, Zuck-Chan & More 09/23/16 National
Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More 08/05/16 National
Shire Steps Back in Hemophilia Gene Therapy Race, Scraps Baxalta Drug 08/03/16 Boston
At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy 07/28/16 National
Magnomics Mastitis Diagnostic Lands Prize, Finds Potential NC Partner 05/23/16 Raleigh Durham
Spark Adds To Early But Promising Data For Hemophilia Gene Therapy 05/19/16 National
With BioMarin Data, Gene Therapy Finally Shows Impact on Hemophilia A 04/20/16 San Francisco
NY Bio Startup Syntimmune Gets $10M From Baxalta, Apple Tree 03/22/16 New York
Precision BioSciences, Chimerix, Spreedly, & More NC Innovation News 02/29/16 Raleigh Durham
UniQure’s Shares Rise on Early Gene Therapy Data For Hemophilia 01/07/16 National
Still Eyeing Baxalta, Shire Pulls Trigger on $6.5B Dyax Buyout 11/02/15 Boston
Bio Slump Hits IPOs as Edge, Mirna Cut Prices, Upsize to Close Deals 10/01/15 New York
Gene Therapy Startup Dimension Tx Takes Crossover Cash to IPO Queue 09/14/15 Boston
East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More 09/04/15 Boston
Shire Sends Hemophilia Gene Editing Prospects Back to Sangamo 09/02/15 San Francisco
East Coast Biotech Roundup: PrecisionFDA, Avitide, Foresight & More 08/07/15 Boston
What Seattle Needs (Part 3): Working Together to Revitalize Biotech 10/08/14 Seattle
East Coast Biotech Roundup: Intarcia, Atlas, Visterra, & More 10/06/14 Boston
Page 1 of 1